Skip to content
Search

Latest Stories

Over 50% of pharmacists with disabilities face workplace discrimination

Over 50% of pharmacists with disabilities face workplace discrimination

‘Employers should create an environment where pharmacists with disabilitiescan work safely and without fear of discrimination’

The Pharmacists' Defence Association Ability Network or PDA Ability Network has released initial findings from its disability discrimination survey, indicating the need for significant efforts to make workplaces more inclusive for pharmacists with disabilities.

Launched in February this year, the survey aims to establish the extent of discrimination faced in the workplace by pharmacists who are disabled or live with a long-term health condition.


Respondents reported encountering disability discrimination in a variety of ways, from employment being withdrawn upon discovery of their disability to employers declining to offer reasonable adjustments.

The initial survey report revealed that 40 per cent of participants expressed feeling excluded from the workforce, underemployed, or unemployed because of their disability.

It was found that nearly 70 per cent of participants either did not receive reasonable adjustments or only received partial reasonable adjustments to accommodate their disability.

More than half of respondents (53 per cent) reported experiencing discrimination in the workplace.

Among those who faced discrimination, 60 per cent said it came from their manager, while 40 per cent reported experiencing discrimination from colleagues.

Liz Larkin, PDA organiser and co-ordinator for the PDA Ability Network, said “Pharmacists are a talented skilled workforce but a proportion of pharmacists who have disabilities or long-term health conditions are discriminated against and excluded from the workforce.

“This is a terrible loss of skills and talent and we need employers to create an environment where disabled members can work safely and without fear of discrimination.”

The network said that it will use this evidence to inform its next campaign to lobby employers to meet their obligations under the Equality Act 2010 to provide reasonable adjustments.

“With one in five people in the UK being disabled, discrimination not only causes real distress, it means that a valued group of the workforce may find themselves not working should their employer not support them,” the network noted.

PDA members are encouraged to complete the online survey by Tuesday 30 April 2024.

More For You

Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less